EYPT Q2 2022 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+28.3% YoY

Gross Profit

$10M85.0% margin

Operating Income

-$19M-166.2% margin

Net Income

-$19M-167.8% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+24.4%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$233M

Total Liabilities

$82M

Stockholders' Equity

$151M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$9M	+28.3%
Gross Profit	$10M	$7M	+38.8%
Operating Income	-$19M	-$11M	-75.0%
Net Income	-$19M	-$10M	-93.9%

Revenue Segments

Y U T I Q Product

$7M66%

D E X Y C U Product

$4M34%